A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma (NEO-MIMAJOR)

Biocad

Status and phase: Enrolling; Phase 3

Conditions: Melanoma Stage III; Melanoma (Skin)

Treatments: Procedure: Excision of the primary lesion; Biological: BCD-217; Biological: anti-PD1; Procedure: Regional lymphadenectomy

Study type: Interventional

Funder types: Industry

Identifiers

NCT05751928

BCD-217-3

Details and patient eligibility

About

This study is an open-label, randomized, comparative phase III study, which will include subjects with resectable stage III skin melanoma (up to 3 resectable transient metastases are acceptable).

Full description

In both study groups, adjuvant therapy is possible until melanoma progresses to unresectable stage III-IV, unacceptable toxicity, withdrawal of ICF or the end of the therapy period (12 months).

In case of postoperative relapse of the disease, at the decision of the investigator and if the lesion is resectable, radical surgical treatment can be carried out (R0 - resection) in accordance with current clinical guidelines without withdrawing the patient from the study.

Enrollment: 410 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Signed informed consent and the subject's ability to comply with the requirements of the clinical study protocol;

2. Age ≥ 18 years at the time of signing the informed consent form;

3. Histologically or cytologically confirmed (documented results of relevant studies are available) resectable stage IIIB/C/D skin melanoma;

4. At least one clinically detectable lymph node accessible for biopsy and not more than three resectable in-transit metastases .

   Clinically detectable lymph nodes include:

   • Palpable lymph nodes with pathologically confirmed melanoma
   • Non-palpable but enlarged (≥15 mm in smallest diameter, RECIST 1.1) lymph nodes with pathologically confirmed melanoma

5. Subject's consent to a biopsy;

6. Consent to the evaluation of the PD-L1 status and BRAF V600 mutation status ;

7. ECOG score 0-1;

8. Life expectancy of at least 5 years;

9. Willingness of subjects and their sexual partners of childbearing potential to use reliable methods of contraception from the date of signing the informed consent form throughout the study period and for 24 weeks after the administration of the last dose of the investigational therapy.

Exclusion criteria

1. Ocular melanoma;

2. Mucosal melanoma;

3. Distant metastases;

4. Impossibility of radical resection of the tumor, metastasis and/or involved lymph nodes;

5. Presence of only in-transit transit/satellite metastases without confirmed involvement of lymph nodes;

6. Prior therapy with checkpoint inhibitors (e.g. anti-CTLA-4 and/or anti-PD-1/PD-L1/PD-L2 products);

7. Prior therapy with BRAF and MEK protein kinase inhibitors;

8. Prior radiation therapy;

9. Inability to determine BRAF status;

10. Subjects with severe comorbidities, with life-threatening acute complications of the underlying disease at the time of signing the informed consent form;

11. Current concomitant diseases at the time of screening, which increase the risk of severe adverse events during surgery and/or study therapy administration;

    • stable angina, functional class III-IV;
    • unstable angina or a history of myocardial infarction within less than 6 months prior to signing the informed consent form;
    • moderate to severe cardiac failure (NYHA classes III and IV);
    • uncontrolled hypertension (systolic blood pressure >150 mmHg or diastolic blood pressure >90 mmHg) ;
    • a history of atopic asthma , angioneurotic edema;
    • respiratory failure (moderate to severe), grade 3 or 4 chronic obstructive pulmonary disease;
    • any other concomitant diseases (including, but not limited to, metabolic, hematological, renal, hepatic, pulmonary, neurological, endocrine, cardiac, infectious, gastrointestinal disorders), which expose the subject to an unacceptable risk during surgery or study therapy;

12. Known or suspected systemic autoimmune diseases (including, but not limited to, systemic lupus erythematosus, Crohn's disease, ulcerative colitis (UC), systemic scleroderma, inflammatory myopathy, mixed connective tissue disease, overlap syndrome, etc.) ;

13. A history of interstitial pulmonary disease or pneumonitis requiring systemic glucocorticoids;

14. The need for glucocorticoid therapy (at >10mg/day prednisolone equivalent doses) or any other drugs with immunosuppressive effects within 6 months prior to randomization;

15. Use of immunostimulants, monoclonal antibodies and/or colony-stimulating factors within less than 4 weeks prior to randomization in the study;

16. Hematological abnormalities :

    • neutrophils <1.5×109/L;
    • platelets <100×109/L;
    • hemoglobin <90 g/L;

17. Renal impairment: creatinine ≥1.5×ULN;

18. Hepatic impairment :

    • Total bilirubin ≥1.3×ULN (except for subjects with Gilbert's syndrome, in whom bilirubin levels should not exceed 50 μmol/L);
    • ALP, AST or ALT ≥1.5×ULN;

19. Any surgery within less than 28 days prior to randomization in the study;

20. History of oncological disease, except for radically treated diseases with remission for over 5 years prior randomization in this study ;

21. Conditions limiting the subject's ability to comply with the Protocol requirements (in the Investigator's opinion );

22. Participation in other clinical studies within less than 30 days prior to randomization and during this clinical study ;

23. Acute infections or activation of chronic infectious diseases or systemic antibacterial therapy within less than 28 days prior to randomization;

24. Active hepatitis B, active hepatitis C (confirmed by PCR), HIV-infection, currently or previously ;

25. Impossibility to administer the investigational product intravenously;

26. Impossibility to administer intravenous contrast agents (including due to hypersensitivity to contrast media);

27. Hypersensitivity to any of the components of BCD-217, prolgolimab or pembrolizumab;

28. A history of hypersensitivity to monoclonal antibody products;

29. Pregnancy or breastfeeding.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

410 participants in 3 patient groups

Subjects with pCR and pnCR (Group 1A)

Experimental group

Description:

Subjects will receive 2 cycles of BCD-217 neoadjuvant therapy, followed by index lymph node removal. Subjects with pathological complete (pCR) and near complete response (pnCR) (Group 1A): excision of the primary lesion (if not previously performed) without regional lymphadenectomy, followed by up to 12 months of anti-PD1 agent in the adjuvant setting.

Treatment:

Biological: anti-PD1

Biological: BCD-217

Procedure: Excision of the primary lesion

Subjects with a pPR or pNR to neoadjuvant therapy (Group 1B)

Experimental group

Description:

Subjects will receive 2 cycles of BCD-217 neoadjuvant therapy, followed by index lymph node removal. Subjects with a pathological partial response (pPR) or non-responders (pNR) to neoadjuvant therapy (Group 1B): excision of the primary lesion (if not performed earlier), regional lymphadenectomy, then up to 12 months of adjuvant therapy with anti-PD1 agent.

Treatment:

Procedure: Regional lymphadenectomy

Biological: anti-PD1

Biological: BCD-217

Procedure: Excision of the primary lesion

Control Group (Group 2)

Active Comparator group

Description:

Subjects start treatment with excision of the primary lesion (if not previously performed), regional lymphadenectomy followed by adjuvant therapy with anti-PD1 agent (up to 12 months). This approach is considered the standard therapy for patients in the target population.

Treatment:

Procedure: Regional lymphadenectomy

Procedure: Excision of the primary lesion